产品
编 号：F757603
分子式：C24H28N2O6S
分子量：472.55
分子式：C24H28N2O6S
分子量：472.55
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 340019-69-4
产品详情
生物活性：
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB).
体内研究：
Dovramilast (oral gavage, 5, 25, or 50 mg/kg, single) significantly improves antibiotic-mediated bacterial killing and reduces lung pathology. Pharmacokinetic Parameters of Dovramilast in B6D2F1 mice.Sampling time(h)Concentration(ng/ml) CC-11050 onlyCC-11050+INH
11,331.6±136.97905.35±594.23
21,409.47±140.851,309.39±214.08
5948.85±128.71,609.18±167.2
8820.6±265.981,271.73±249.18
241.27±1.14.96±1.85
Tmax(h)2.05.0
Cmax(ng/ml)1,4101,610
AUClast(ng × h/ml)10,20013,900
Animal Model:B6D2F1 mice
Dosage:5, 25, or 50 mg/kg
Administration:oral, 5, 25, or 50 mg/kg, single
Result:Reduced PDE4 expression in mtb-infected mouse lungs.
Animal Model:B6D2F1 mice
Dosage:5, 25, or 50 mg/kg
Administration:oral gavage, 5, 25, or 50 mg/kg, single
Result:Improved antibiotic-mediated bacterial killing and reduced lung pathology.
Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (INH)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB).
体内研究：
Dovramilast (oral gavage, 5, 25, or 50 mg/kg, single) significantly improves antibiotic-mediated bacterial killing and reduces lung pathology. Pharmacokinetic Parameters of Dovramilast in B6D2F1 mice.Sampling time(h)Concentration(ng/ml) CC-11050 onlyCC-11050+INH
11,331.6±136.97905.35±594.23
21,409.47±140.851,309.39±214.08
5948.85±128.71,609.18±167.2
8820.6±265.981,271.73±249.18
241.27±1.14.96±1.85
Tmax(h)2.05.0
Cmax(ng/ml)1,4101,610
AUClast(ng × h/ml)10,20013,900
Animal Model:B6D2F1 mice
Dosage:5, 25, or 50 mg/kg
Administration:oral, 5, 25, or 50 mg/kg, single
Result:Reduced PDE4 expression in mtb-infected mouse lungs.
Animal Model:B6D2F1 mice
Dosage:5, 25, or 50 mg/kg
Administration:oral gavage, 5, 25, or 50 mg/kg, single
Result:Improved antibiotic-mediated bacterial killing and reduced lung pathology.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备